Please login to the form below
epigenetics
This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.
GSK: we won’t be splitting up any time soon
Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
Latest news
-
AstraZeneca to explore link between epigenetics and respiratory diseases
AstraZeneca to explore link between epigenetics and respiratory diseases. Joins forces with Asthma UK, the British Lung Foundation and MRC Technology. ... Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the
-
Biogen buys into Rodin's Alzheimer's candidate
Biogen buys into Rodin's Alzheimer's candidate. And may acquire the epigenetics-focused Massachusetts firm. ... Biogen has its own research programme in neuronal epigenetic research, according to Samantha Budd Haeberlein, Biogen's vice president of
-
Novartis' Farydak gets nod for myeloma in Europe
Novartis says its approval marks "the first time an HDAC inhibitor with epigenetic activity is available in the EU," providing a much-needed additional line of therapy for patients with aggressive
-
Celgene to acquire biotech firm Quanticel Pharmaceuticals
Through the agreement, Celgene will have full access to Quanticel's proprietary platform for the single-cell genomic analysis of human cancer, alongside Quanticel's lead programmes that target specific epigenetic
-
Novartis pays $16bn for GSK's oncology portfolio
on cancer immunotherapy, epigenetics and tumour environment.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
-
Opening up innovation
So that is really about the late-stage portfolio. We [are still] focused on three areas in oncology.” These are cancer epigenetics, immuno-oncology and cell and gene therapy in oncology. “
-
Deal Watch January 2016
Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
-
Deal Watch October 2015
Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
-
Pharma deals in August 2015
This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Professor Thomas Cech joins Storm Therapeutics
mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
-
Storm Therapeutics strengthens its board
RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
-
Rubius Therapeutics strengthens senior team
He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
-
Account Director
-
Excellent benefits
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Medical/ Scientific Director
-
Salary TBC
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical Writers
-
Competitive Salary and Benefits
-
Associate Medical Director
-
Highly Competitive
-
Associate Director
-
£75, 000-90, 000
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Director, Market Access / HEOR - North-West
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
Senior Medical Writer
-
Great salary and benefits
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
Subscribe to our email news alerts
- Key considerations for disease- modifying Parkinson’s disease trials
- Artificial Intelligence In Healthcare Market to Witness Exponential Growth by 2027
- Breathing Exercise Devices Market Intelligence Report Offers Growth Prospects
- Micro-CT Scanners Market 10-Year Market Forecast and Trends Analysis Research Report
- Next Generation Infusion Pump Market Healthy Pace throughout the Forecast during 2017 – 2027
- Wireless Brain Sensors Market Intelligence Report Offers Growth Prospects
PMHub
Six Degrees Medical Consulting
Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
